RxDoctor Payments Data

Nicholas Freidberg, MD

Urology · Austin, TXNPI 1578910261

Payments from drug & device makers

$2,955in general payments, 2019–2025

Across 98 payments — averaging $30.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$482
  • Pfizer$325
  • Sumitomo Pharma America, Inc.$290
  • Cook Medical LLC$282
  • Olympus America Inc.$164
  • Biotissue Holdings Inc.$158
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$2,951100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,955 in reported general payments places this provider in the 40th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$221,374
Medicare patients
446
Services billed
7,383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix34$87,581
GemtesaVibegron41$31,693
MyrbetriqMirabegron36$23,785
Abiraterone Acetate12$8,247
Mirabegron ErMirabegron11$6,095
Tamsulosin Hcl387$5,313
Testosterone Cypionate30$1,619
Estradiol28$1,456
Finasteride79$1,178
Solifenacin Succinate63$1,146
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav88$695
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst17$381
Alfuzosin Hcl ErAlfuzosin Hcl13$249
Ciprofloxacin Hcl35$178
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim29$125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$290$119,27475 claims
Astellas Pharma US IncMyrbetriq$53$23,78536 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 878 urology providers in Texas.

Other urology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →